このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis (HILT-ESCOA)

2026年10月5日 更新者:Prof. Dr. Simin Hepgüler、Ege University

Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis: A Randomized Controlled Trial

This randomized, double-blind, sham-controlled clinical trial evaluated the effectiveness of high-intensity laser therapy (HILT) in patients with early-stage symptomatic knee osteoarthritis.

A total of 39 participants were randomly assigned to receive either HILT combined with a standardized home exercise program or sham laser therapy combined with the same exercise program. Laser or sham treatment was administered over 10 weekday sessions during a two-week period.

Participants were assessed at baseline, immediately after treatment, and at the three-month follow-up. Assessments included pain intensity, physical function, health-related quality of life, walking performance, knee range of motion, and muscle strength.

The aim was to determine whether adding HILT to exercise provides additional clinical benefits compared with sham laser therapy combined with exercise.

調査の概要

研究の種類

介入

入学 (実際)

39

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • İzmir
      • Izmir、İzmir、トルコ(Türkiye)、35100
        • Ege University Faculty of Medicine Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Inclusion Criteria:

    1. Patients presenting to the Physical Medicine and Rehabilitation outpatient clinics of Ege University Faculty of Medicine Hospital with knee pain lasting no longer than 6 months and a Visual Analog Scale (VAS) pain score of at least 4.
    2. Availability of bilateral weight-bearing knee radiographs in two views obtained within the preceding 6 months.
    3. Diagnosis of early symptomatic knee osteoarthritis according to the Italian Society of Rheumatology International Initiative (ESKOA) criteria.
    4. Ability to cooperate with the prescribed exercise program.
    5. Willingness to participate in the study and provision of informed consent.
    6. Age eligibility:
  • 40-49 years: Presence of at least one of the following risk factors for early symptomatic knee osteoarthritis.

  • 50-75 years: Eligible regardless of the presence of the listed risk factors.

Risk factors:

  • Body mass index (BMI) greater than 25 kg/m².
  • Family history of knee osteoarthritis.
  • Previous knee injury.
  • Lower-limb alignment abnormality.
  • Lower-limb length discrepancy.
  • Osteoarthritis at other anatomical sites.
  • Metabolic syndrome.
  • Difficulty initiating brisk walking or running after a period of inactivity.

Exclusion Criteria:

  1. Receipt of an intra-articular knee injection or physical therapy within the preceding 6 months, or use of natural health products such as glucosamine or chondroitin.

  2. History of knee surgery.

  3. Presence of inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, or gouty arthritis.

  4. History of trauma within the preceding 6 months.

  5. Fixed knee flexion deformity greater than 10 degrees or varus/valgus deformity greater than 15 degrees.

  6. Referred pain originating from the lumbar spine or hip.

  7. Neurological deficits affecting the lower extremities.

  8. Medical conditions that could prevent participation in the exercise program or completion of the study, including:

    • Myocardial infarction or cerebrovascular event within the preceding 3 months.
    • Congestive heart failure.
    • Severe chronic obstructive pulmonary disease.
    • History of myocardial ischemia during treadmill testing.
    • History of arterial or venous circulatory disorders.
  9. Presence of a cardiac pacemaker or metal implants.

  10. Pregnancy.

  11. History of malignancy, knee osteonecrosis, infectious disease, psychiatric illness, or bleeding diathesis.

  12. Epilepsy.

  13. Conditions impairing cooperation or communication, including language barriers, aphasia, marked affective disorders, or a history of severe psychiatric illness.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:HILT + Exercise

Participants received high-intensity laser therapy (HILT) combined with a standardized home exercise program. HILT was administered in 10 sessions over two consecutive weeks (five sessions per week). Participants also performed the prescribed home exercise program throughout the treatment period.

High-intensity laser therapy (HILT) was administered using a 1064-nm laser at a frequency of 20 Hz, with an energy density of 1530 mJ/cm² and a total energy of 3000 J per session. Treatment consisted of 10 sessions administered on consecutive weekdays over a two-week period. HILT was combined with a standardized home exercise program.

Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment.

偽コンパレータ:Sham Laser + Exercise

Participants received sham laser therapy combined with the same standardized home exercise program as the experimental group. The sham procedure was administered without therapeutic laser energy in 10 sessions over two consecutive weeks (five sessions per week).

Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment.

Sham laser therapy was administered using the same treatment schedule and application procedure as the active HILT group, but without delivering therapeutic laser energy. Participants received 10 sham sessions over two consecutive weeks (five sessions per week), combined with the same standardized home exercise program.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pain Intensity Assessed by Visual Analog Scale (VAS)
時間枠:Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Pain intensity was assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Knee Symptoms and Physical Function Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
時間枠:Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Knee osteoarthritis-related symptoms and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), including pain, stiffness, and physical function subscales. Higher scores indicate greater symptom severity and functional impairment.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline

二次結果の測定

結果測定
メジャーの説明
時間枠
Functional Status Assessed by Health Assessment Questionnaire (HAQ)
時間枠:Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Functional status and activities of daily living were assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI). Scores range from 0 to 3, with higher scores indicating greater disability and poorer functional status.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Physical Component Summary (PCS)
時間枠:Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Physical health-related quality of life was assessed using the Physical Component Summary (PCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better physical health-related quality of life.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Mental Component Summary (MCS)
時間枠:Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Mental health-related quality of life was assessed using the Mental Component Summary (MCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better mental health-related quality of life.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline

その他の成果指標

結果測定
メジャーの説明
時間枠
Functional Exercise Capacity Assessed by 6-Minute Walk Test (6MWT)
時間枠:Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Functional exercise capacity was assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes was recorded in meters. A greater walking distance indicates better functional exercise capacity.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Knee Range of Motion (ROM)
時間枠:Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Knee range of motion was assessed using a goniometer. Active and passive knee range of motion were measured in degrees.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Lower Extremity Muscle Strength Assessed by Manual Muscle Testing (MMT)
時間枠:Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Lower extremity muscle strength was assessed using manual muscle testing (MMT). Muscle strength was graded on a 0-to-5 scale, with higher scores indicating greater muscle strength.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Paracetamol Use
時間枠:Throughout the study period, from baseline to the 3-month follow-up

Paracetamol use was monitored using a patient diary to assess analgesic use during the study. Changes in paracetamol use were evaluated as an additional indicator of treatment effectiveness.

Throughout the study period, from baseline to the 3-month follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:A.Simin Hepgüler, MD、Ege University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年6月5日

一次修了 (実際)

2026年1月18日

研究の完了 (実際)

2026年1月18日

試験登録日

最初に提出

2026年9月30日

QC基準を満たした最初の提出物

2026年9月30日

最初の投稿 (実際)

2026年10月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月8日

QC基準を満たした最後の更新が送信されました

2026年10月5日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data may be made available from the corresponding author upon reasonable request, subject to ethical and institutional approval.

IPD 共有時間枠

De-identified individual participant data will be available upon reasonable request following publication of the manuscript.

IPD 共有アクセス基準

De-identified individual participant data may be shared with qualified researchers upon reasonable request to the corresponding author (silaolmez@yahoo.com.tr), subject to ethical and institutional approval.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する